Tardive dyskinesia (TD) is a neurological disorder characterized by involuntary movements, often caused by dopamine receptor antagonists. Vesicular monoamine transporter 2 (VMAT2) inhibitors, such as valbenazine and deutetrabenazine, have emerged as promising therapies for TD, with several clinical trials demonstrating their efficacy. This study compares the efficacy and safety profiles of VMAT2 inhibitors, focusing on a recent trial conducted in the Asian population.

Results from four double-blind clinical trials revealed that deutetrabenazine significantly improved Abnormal Involuntary Movement Scale scores compared to placebo, without increasing adverse events. Valbenazine also showed favorable results in reducing TD symptoms and was well-tolerated. The reviewed studies highlight the potential of deutetrabenazine and valbenazine as effective treatments for TD across diverse populations, demonstrating significant symptom improvement and favorable safety profiles with low rates of serious adverse events. These findings offer hope for individuals impacted by TD.

Reference: Golsorkhi M, Koch J, Pedouim F, Frei K, Bondariyan N, Dashtipour K. Comparative Analysis of Deutetrabenazine and Valbenazine as VMAT2 Inhibitors for Tardive Dyskinesia: A Systematic Review. Tremor Other Hyperkinet Mov (N Y). 2024;14:13. doi: 10.5334/tohm.842.